EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials

Journal of Molecular Neuroscience

Volumn 24, Issue 1, 2004, Pages 105-113

  Lavie, Vered ^a   Becker, Maria ^a   Cohen Kupiec, Rachel ^a   Yacoby, Iftach ^a   Koppel, Rela ^a   Wedenig, Manuela ^b   Hutter Paier, Birgit ^b   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b JSW Life Sciences GmbH   (Austria)

Author keywords

amyloid; Cognitive functions; Phage EFRH; Site directed antibodies

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; GLUTAMYLPHENYLALANYLARGINYL HISTIDINE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ANTIBODY; EPITOPE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; BACTERIOPHAGE; BEHAVIOR; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; GENE SEQUENCE; HUMORAL IMMUNITY; IMMUNIZATION; MAZE TEST; MOUSE; NONHUMAN; TASK PERFORMANCE; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; DISEASE MODEL; DOWN REGULATION; GENE DOSAGE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALIA;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BACTERIOPHAGES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPITOPES; GENE DOSAGE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MAZE LEARNING; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 13544277841     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:24:1:105     Document Type: Conference Paper

References (13)

1. Bard F., Barbour R., Cannon C., Carretto R., Games D., Guido T., et al. (2003) Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100(4), 2023-2028.
2. Bard F., Cannon C., Barbour R., Burke R.-.L., Games D., Grajeda H., et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-920.
3. Dodart J., Bales K. R., Gannon K. S., Greene S. J., DeMattos R. B., Mathis C., et al. (2002) Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457.
4. Frenkel D., Balass M., and Solomon B. (1998) N-Terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. 88, 85-90.
5. Frenkel D., Dewachter I., Van Leuven F., and Solomon B. (2003) Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21(11-12), 1060-1065.
6. Frenkel D., Kariv N., and Solomon B. (2001) Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 19, 2615-2619.
7. Frenkel D., Katz O., and Solomon B.(2000) Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U. S. A. 97(21), 11455-11459.
8. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., et al. (2000) Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
9. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
10. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. (1999). Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
11. Solomon B., Koppel R., Frankel D., and Hanan-Aharon E. (1997) Disaggregation of Alzheimer's beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA. 94, 4109-4112.
12. Solomon B., Koppel R., Hannan E., and Katzav T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer's β-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 93, 452-455.
13. Weiner H. L., Lemere C. A., Maron R., Spooner E. T., Grenfell T. J., Mori C., et al. (2000) Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567-579.